Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 451

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 451
---
, including patent or stockholder litigation; |

| • |     | if securities or industry analysts do not publish research or reports about our business, or if they issue an 
 adverse or misleading opinion regarding our business and stock;                                               |

| • |     | changes in the market valuations of similar companies; |

| • |     | general and industry-specific economic conditions potentially affecting our research and development 
 expenditures;                                                                                        |

| • |     | sales of our common stock by us or our stockholders in the future, or the anticipation thereof; |

| • |     | trading volume of our common stock; |

| • |     | changes in the structure of health care payment systems; |

| • |     | adverse regulatory decisions; |

| • |     | trading volume of our common stock; and |

| • |     | period-to-period fluctuations in 
 our financial results.           |

Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies or the biotechnology sector. These broad market fluctuations may also adversely affect the trading price of our common stock. In the past, following periods of volatility in the market price of a company’s securities, stockholders have often instituted class action securities litigation against those companies. Regardless of the merits or the ultimate results of such litigation, if instituted, such litigation could result in substantial costs and diversion of management’s attention and resources, which could significantly harm our profitability and reputation. Additionally, a decrease in our stock price may cause our common stock to no longer satisfy the continued listing standards of Nasdaq. If we are not able to maintain the requirements for listing on Nasdaq, we could be delisted, which could have a materially adverse effect on our ability to raise additional funds as well as the price and liquidity of our common stock. We must maintain effective internal control over financial reporting, and if we are unable to do so, the accuracy and timeliness of our financial reporting may be adversely affected, which could have a material adverse effect on our business and stock price. We must maintain effective internal control over financial reporting in order to accurately and timely report our results of operations and financial condition. In addition, as a public company, the Sarbanes-Oxley Act requires, among other things, that we assess the effectiveness of our disclosure controls and procedures quarterly and the effectiveness of our internal control over financial reporting at the end of each fiscal year. We rely heavily on direct management oversight of transactions, along with the use of legal and outsourced accounting